Farzin Haque
Stock Analyst at Jefferies
(2.78)
# 2,778
Out of 4,504 analysts
11
Total ratings
63.6%
Success rate
9.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Farzin Haque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Initiated Coverage: Buy | $50 | $19.14 | +161.23% | 1 | Mar 29, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $9 | $6.41 | +40.41% | 1 | Dec 21, 2025 | |
| VERA Vera Therapeutics | Maintained: Buy | $57 → $45 | $42.00 | +7.14% | 4 | Nov 26, 2025 | |
| RIGL Rigel Pharmaceuticals | Upgraded: Buy | $42 | $42.55 | -1.29% | 1 | Nov 5, 2025 | |
| NUVB Nuvation Bio | Initiated Coverage: Buy | $10 | $5.81 | +72.12% | 1 | Sep 29, 2025 | |
| HOWL Werewolf Therapeutics | Initiated Coverage: Buy | $4 | $0.403 | +892.56% | 1 | Aug 4, 2025 | |
| PYXS Pyxis Oncology | Maintained: Buy | $10 → $6 | $2.67 | n/a | 2 | Mar 18, 2025 |
Vor Biopharma
Mar 29, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $19.14
Upside: +161.23%
Relmada Therapeutics
Dec 21, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $6.41
Upside: +40.41%
Vera Therapeutics
Nov 26, 2025
Maintained: Buy
Price Target: $57 → $45
Current: $42.00
Upside: +7.14%
Rigel Pharmaceuticals
Nov 5, 2025
Upgraded: Buy
Price Target: $42
Current: $42.55
Upside: -1.29%
Nuvation Bio
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $5.81
Upside: +72.12%
Werewolf Therapeutics
Aug 4, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $0.403
Upside: +892.56%
Pyxis Oncology
Mar 18, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $2.67
Upside: n/a